Stem definition | Drug id | CAS RN |
---|---|---|
dipeptidyl aminopeptidase-IV inhibitors | 4175 | 668270-12-0 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 16 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 129 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
May 2, 2011 | FDA | BOEHRINGER INGELHEIM | |
July 1, 2011 | PMDA | Nippon Boehringer Ingelheim Co., Ltd |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Diabetic ketoacidosis | 235.57 | 14.40 | 109 | 12877 | 19806 | 53316274 |
Pancreatitis | 207.53 | 14.40 | 133 | 12853 | 46009 | 53290071 |
Hypoglycaemia | 191.45 | 14.40 | 139 | 12847 | 58874 | 53277206 |
Pemphigoid | 190.05 | 14.40 | 68 | 12918 | 6376 | 53329704 |
Blood glucose increased | 182.86 | 14.40 | 151 | 12835 | 77210 | 53258870 |
Euglycaemic diabetic ketoacidosis | 128.89 | 14.40 | 42 | 12944 | 2965 | 53333115 |
Glycosylated haemoglobin increased | 102.17 | 14.40 | 52 | 12934 | 11603 | 53324477 |
Hyperglycaemia | 83.82 | 14.40 | 73 | 12913 | 40011 | 53296069 |
Acute kidney injury | 83.59 | 14.40 | 188 | 12798 | 253680 | 53082400 |
Renal impairment | 78.48 | 14.40 | 99 | 12887 | 83219 | 53252861 |
Hyperlactacidaemia | 70.07 | 14.40 | 26 | 12960 | 2699 | 53333381 |
Metabolic acidosis | 65.26 | 14.40 | 65 | 12921 | 42177 | 53293903 |
Pancreatitis acute | 61.64 | 14.40 | 51 | 12935 | 26058 | 53310022 |
Ketoacidosis | 61.08 | 14.40 | 27 | 12959 | 4399 | 53331681 |
Lactic acidosis | 58.79 | 14.40 | 58 | 12928 | 37195 | 53298885 |
Pancreatic carcinoma | 57.97 | 14.40 | 30 | 12956 | 6924 | 53329156 |
Glomerular filtration rate decreased | 57.80 | 14.40 | 37 | 12949 | 12730 | 53323350 |
Diabetes mellitus inadequate control | 53.96 | 14.40 | 37 | 12949 | 14273 | 53321807 |
Dermatitis bullous | 53.45 | 14.40 | 30 | 12956 | 8133 | 53327947 |
Rheumatoid arthritis | 50.67 | 14.40 | 8 | 12978 | 314523 | 53021557 |
Blood glucose abnormal | 48.20 | 14.40 | 27 | 12959 | 7292 | 53328788 |
Diabetic metabolic decompensation | 47.31 | 14.40 | 17 | 12969 | 1611 | 53334469 |
Hyperkalaemia | 45.63 | 14.40 | 61 | 12925 | 54195 | 53281885 |
Fungal infection | 43.24 | 14.40 | 46 | 12940 | 32200 | 53303880 |
Pain | 40.94 | 14.40 | 50 | 12936 | 588348 | 52747732 |
Renal failure | 36.94 | 14.40 | 86 | 12900 | 118366 | 53217714 |
Chronic kidney disease | 36.83 | 14.40 | 49 | 12937 | 43321 | 53292759 |
Dizziness | 36.57 | 14.40 | 183 | 12803 | 372076 | 52964004 |
Cardiac failure | 35.62 | 14.40 | 70 | 12916 | 85774 | 53250306 |
Subarachnoid haemorrhage | 31.81 | 14.40 | 25 | 12961 | 11868 | 53324212 |
Blood glucose decreased | 29.43 | 14.40 | 30 | 12956 | 19986 | 53316094 |
Shock | 29.25 | 14.40 | 32 | 12954 | 23107 | 53312973 |
Diabetes mellitus | 28.74 | 14.40 | 49 | 12937 | 53850 | 53282230 |
Insulin-like growth factor decreased | 26.82 | 14.40 | 8 | 12978 | 421 | 53335659 |
Drug ineffective | 26.54 | 14.40 | 106 | 12880 | 817139 | 52518941 |
Lethargy | 26.23 | 14.40 | 47 | 12939 | 53713 | 53282367 |
Mucosal membrane hyperplasia | 25.01 | 14.40 | 5 | 12981 | 46 | 53336034 |
Hypoglycaemic encephalopathy | 24.95 | 14.40 | 7 | 12979 | 296 | 53335784 |
Urine calcium/creatinine ratio increased | 24.05 | 14.40 | 6 | 12980 | 160 | 53335920 |
Lipase increased | 23.56 | 14.40 | 19 | 12967 | 9359 | 53326721 |
Urinary tract infection | 23.54 | 14.40 | 118 | 12868 | 239785 | 53096295 |
Completed suicide | 23.43 | 14.40 | 3 | 12983 | 138198 | 53197882 |
Contraindicated product administered | 22.85 | 14.40 | 3 | 12983 | 135626 | 53200454 |
Altered state of consciousness | 22.54 | 14.40 | 29 | 12957 | 24807 | 53311273 |
Bite | 22.51 | 14.40 | 7 | 12979 | 424 | 53335656 |
Albuminuria | 21.90 | 14.40 | 6 | 12980 | 232 | 53335848 |
Blood creatinine increased | 21.49 | 14.40 | 56 | 12930 | 82606 | 53253474 |
Vomiting | 20.73 | 14.40 | 198 | 12788 | 496941 | 52839139 |
Systemic lupus erythematosus | 20.60 | 14.40 | 3 | 12983 | 125411 | 53210669 |
Urethral caruncle | 20.12 | 14.40 | 5 | 12981 | 131 | 53335949 |
Decreased appetite | 19.18 | 14.40 | 103 | 12883 | 214871 | 53121209 |
Parathyroid hyperplasia | 18.84 | 14.40 | 5 | 12981 | 171 | 53335909 |
Pruritus | 18.14 | 14.40 | 128 | 12858 | 293704 | 53042376 |
Blood potassium increased | 18.05 | 14.40 | 22 | 12964 | 17819 | 53318261 |
Hypomagnesaemia | 18.01 | 14.40 | 26 | 12960 | 24785 | 53311295 |
Mesenteric vein thrombosis | 16.46 | 14.40 | 7 | 12979 | 1038 | 53335042 |
Hypophagia | 16.24 | 14.40 | 28 | 12958 | 31034 | 53305046 |
Food refusal | 15.86 | 14.40 | 5 | 12981 | 317 | 53335763 |
Drug intolerance | 15.83 | 14.40 | 16 | 12970 | 205477 | 53130603 |
Blood glucose fluctuation | 15.36 | 14.40 | 11 | 12975 | 4540 | 53331540 |
Pancreatic enzymes increased | 15.35 | 14.40 | 6 | 12980 | 717 | 53335363 |
Arthropathy | 14.78 | 14.40 | 8 | 12978 | 141445 | 53194635 |
Pyelonephritis | 14.61 | 14.40 | 19 | 12967 | 16418 | 53319662 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pemphigoid | 459.71 | 13.76 | 168 | 15732 | 8268 | 32489358 |
Pancreatitis | 218.38 | 13.76 | 167 | 15733 | 37984 | 32459642 |
Hypoglycaemia | 168.90 | 13.76 | 168 | 15732 | 54214 | 32443412 |
Diabetic ketoacidosis | 157.32 | 13.76 | 102 | 15798 | 17830 | 32479796 |
Glycosylated haemoglobin increased | 148.55 | 13.76 | 81 | 15819 | 10308 | 32487318 |
Blood glucose increased | 132.03 | 13.76 | 161 | 15739 | 65080 | 32432546 |
Dermatitis bullous | 107.50 | 13.76 | 56 | 15844 | 6497 | 32491129 |
Euglycaemic diabetic ketoacidosis | 96.43 | 13.76 | 40 | 15860 | 2758 | 32494868 |
Blood mercury abnormal | 75.37 | 13.76 | 18 | 15882 | 189 | 32497437 |
5-hydroxyindolacetic acid in urine increased | 73.33 | 13.76 | 18 | 15882 | 214 | 32497412 |
Cardiac failure | 66.85 | 13.76 | 142 | 15758 | 91531 | 32406095 |
Pericardial disease | 52.53 | 13.76 | 15 | 15885 | 329 | 32497297 |
Cerebral infarction | 50.73 | 13.76 | 65 | 15835 | 27549 | 32470077 |
Left ventricular dysfunction | 50.09 | 13.76 | 40 | 15860 | 9655 | 32487971 |
Pancreatic carcinoma | 48.84 | 13.76 | 37 | 15863 | 8269 | 32489357 |
Low density lipoprotein decreased | 46.50 | 13.76 | 18 | 15882 | 1035 | 32496591 |
Pulmonary valve disease | 46.24 | 13.76 | 13 | 15887 | 269 | 32497357 |
Pancreatitis acute | 45.04 | 13.76 | 61 | 15839 | 27274 | 32470352 |
Diastolic dysfunction | 44.03 | 13.76 | 29 | 15871 | 5195 | 32492431 |
Mean platelet volume increased | 43.56 | 13.76 | 14 | 15886 | 463 | 32497163 |
Ventricular hyperkinesia | 43.26 | 13.76 | 12 | 15888 | 236 | 32497390 |
Hyperglycaemia | 42.30 | 13.76 | 71 | 15829 | 38320 | 32459306 |
Ketoacidosis | 42.28 | 13.76 | 26 | 15874 | 4138 | 32493488 |
Right atrial enlargement | 42.16 | 13.76 | 12 | 15888 | 260 | 32497366 |
Hepatic neoplasm | 40.62 | 13.76 | 20 | 15880 | 2058 | 32495568 |
Hypochromasia | 39.01 | 13.76 | 12 | 15888 | 343 | 32497283 |
Mitral valve thickening | 36.75 | 13.76 | 12 | 15888 | 418 | 32497208 |
Acute kidney injury | 36.08 | 13.76 | 256 | 15644 | 293212 | 32204414 |
Stenosis | 36.00 | 13.76 | 15 | 15885 | 1045 | 32496581 |
Diabetic nephropathy | 34.11 | 13.76 | 18 | 15882 | 2141 | 32495485 |
Rales | 33.66 | 13.76 | 29 | 15871 | 7772 | 32489854 |
Blood glucose abnormal | 33.09 | 13.76 | 25 | 15875 | 5563 | 32492063 |
Left atrial enlargement | 31.79 | 13.76 | 12 | 15888 | 644 | 32496982 |
Renal impairment | 31.71 | 13.76 | 108 | 15792 | 91864 | 32405762 |
Left ventricular enlargement | 31.66 | 13.76 | 12 | 15888 | 651 | 32496975 |
Haematocrit increased | 31.60 | 13.76 | 16 | 15884 | 1747 | 32495879 |
Expired product administered | 30.71 | 13.76 | 19 | 15881 | 3056 | 32494570 |
Physical examination abnormal | 30.40 | 13.76 | 9 | 15891 | 225 | 32497401 |
Necrotising oesophagitis | 29.49 | 13.76 | 11 | 15889 | 571 | 32497055 |
Tricuspid valve incompetence | 29.33 | 13.76 | 29 | 15871 | 9258 | 32488368 |
Neoplasm | 29.00 | 13.76 | 21 | 15879 | 4380 | 32493246 |
Mucosal dryness | 28.65 | 13.76 | 13 | 15887 | 1114 | 32496512 |
Diabetes mellitus | 28.39 | 13.76 | 66 | 15834 | 45107 | 32452519 |
Pericardial haemorrhage | 28.14 | 13.76 | 18 | 15882 | 3068 | 32494558 |
Diabetes mellitus inadequate control | 27.81 | 13.76 | 34 | 15866 | 13734 | 32483892 |
Completed suicide | 27.17 | 13.76 | 6 | 15894 | 92511 | 32405115 |
Drug abuse | 26.15 | 13.76 | 4 | 15896 | 80239 | 32417387 |
Blood iron decreased | 25.56 | 13.76 | 20 | 15880 | 4684 | 32492942 |
Glomerular filtration rate decreased | 24.85 | 13.76 | 31 | 15869 | 12780 | 32484846 |
Cardiac discomfort | 24.07 | 13.76 | 9 | 15891 | 470 | 32497156 |
Haemoglobin increased | 23.31 | 13.76 | 16 | 15884 | 3066 | 32494560 |
Hypovolaemia | 23.12 | 13.76 | 25 | 15875 | 8852 | 32488774 |
Amylase increased | 23.11 | 13.76 | 21 | 15879 | 6034 | 32491592 |
Mitral valve incompetence | 22.71 | 13.76 | 32 | 15868 | 14839 | 32482787 |
Chronic kidney disease | 22.53 | 13.76 | 56 | 15844 | 39919 | 32457707 |
Left atrial dilatation | 22.41 | 13.76 | 13 | 15887 | 1859 | 32495767 |
Interstitial lung disease | 22.10 | 13.76 | 76 | 15824 | 64925 | 32432701 |
Hypohidrosis | 21.74 | 13.76 | 7 | 15893 | 233 | 32497393 |
Hypoglycaemic coma | 21.66 | 13.76 | 14 | 15886 | 2429 | 32495197 |
Bronchitis viral | 21.13 | 13.76 | 7 | 15893 | 255 | 32497371 |
Hypervolaemia | 20.99 | 13.76 | 14 | 15886 | 2560 | 32495066 |
Lipase increased | 20.57 | 13.76 | 24 | 15876 | 9233 | 32488393 |
Dropped head syndrome | 20.31 | 13.76 | 6 | 15894 | 149 | 32497477 |
Neutropenia | 20.07 | 13.76 | 24 | 15876 | 142151 | 32355475 |
Bundle branch block left | 20.04 | 13.76 | 19 | 15881 | 5760 | 32491866 |
Peak expiratory flow rate decreased | 19.90 | 13.76 | 6 | 15894 | 160 | 32497466 |
Poikilocytosis | 19.62 | 13.76 | 6 | 15894 | 168 | 32497458 |
Urine ketone body present | 19.48 | 13.76 | 10 | 15890 | 1124 | 32496502 |
Hypertensive heart disease | 19.09 | 13.76 | 13 | 15887 | 2459 | 32495167 |
Diabetic ketoacidotic hyperglycaemic coma | 19.07 | 13.76 | 6 | 15894 | 185 | 32497441 |
Hyperkalaemia | 19.05 | 13.76 | 76 | 15824 | 69674 | 32427952 |
Red blood cell count decreased | 18.98 | 13.76 | 42 | 15858 | 27771 | 32469855 |
Genital infection fungal | 18.77 | 13.76 | 6 | 15894 | 195 | 32497431 |
Echocardiogram abnormal | 18.58 | 13.76 | 9 | 15891 | 894 | 32496732 |
Ventricular arrhythmia | 18.19 | 13.76 | 17 | 15883 | 5062 | 32492564 |
Mitral valve disease | 18.17 | 13.76 | 10 | 15890 | 1294 | 32496332 |
Blindness transient | 18.02 | 13.76 | 12 | 15888 | 2189 | 32495437 |
Rhinalgia | 17.97 | 13.76 | 7 | 15893 | 409 | 32497217 |
Lactic acidosis | 17.87 | 13.76 | 46 | 15854 | 33490 | 32464136 |
General physical health deterioration | 17.87 | 13.76 | 18 | 15882 | 115241 | 32382385 |
Electrocardiogram T wave inversion | 17.85 | 13.76 | 12 | 15888 | 2222 | 32495404 |
Hepatic function abnormal | 17.54 | 13.76 | 55 | 15845 | 44785 | 32452841 |
Blood phosphorus increased | 17.40 | 13.76 | 13 | 15887 | 2844 | 32494782 |
Blood chloride increased | 16.84 | 13.76 | 13 | 15887 | 2986 | 32494640 |
Death | 16.77 | 13.76 | 114 | 15786 | 382403 | 32115223 |
Haemodynamic instability | 16.58 | 13.76 | 21 | 15879 | 8790 | 32488836 |
Hyperlactacidaemia | 16.55 | 13.76 | 13 | 15887 | 3061 | 32494565 |
Drug ineffective | 16.46 | 13.76 | 115 | 15785 | 383362 | 32114264 |
Erythema multiforme | 16.24 | 13.76 | 21 | 15879 | 8971 | 32488655 |
Hyperaesthesia teeth | 15.98 | 13.76 | 7 | 15893 | 552 | 32497074 |
Supraventricular tachycardia | 15.94 | 13.76 | 23 | 15877 | 10893 | 32486733 |
Dust allergy | 15.90 | 13.76 | 7 | 15893 | 558 | 32497068 |
High density lipoprotein decreased | 15.56 | 13.76 | 13 | 15887 | 3339 | 32494287 |
Product use in unapproved indication | 15.46 | 13.76 | 12 | 15888 | 87192 | 32410434 |
Epidermolysis | 15.38 | 13.76 | 6 | 15894 | 352 | 32497274 |
Gastric cancer | 15.38 | 13.76 | 16 | 15884 | 5421 | 32492205 |
Marasmus | 15.08 | 13.76 | 7 | 15893 | 632 | 32496994 |
Metabolic acidosis | 15.08 | 13.76 | 49 | 15851 | 40650 | 32456976 |
Acute lung injury | 15.00 | 13.76 | 9 | 15891 | 1369 | 32496257 |
Skin disorder | 14.94 | 13.76 | 24 | 15876 | 12480 | 32485146 |
Pain | 14.75 | 13.76 | 45 | 15855 | 187511 | 32310115 |
Urticaria | 14.74 | 13.76 | 63 | 15837 | 59551 | 32438075 |
Respiratory symptom | 14.60 | 13.76 | 8 | 15892 | 1026 | 32496600 |
Blood uric acid increased | 14.48 | 13.76 | 17 | 15883 | 6582 | 32491044 |
Eosinophil count increased | 14.29 | 13.76 | 19 | 15881 | 8336 | 32489290 |
Drug eruption | 14.29 | 13.76 | 30 | 15870 | 19136 | 32478490 |
Femoral neck fracture | 14.16 | 13.76 | 12 | 15888 | 3144 | 32494482 |
Bronchial hyperreactivity | 13.86 | 13.76 | 9 | 15891 | 1573 | 32496053 |
Source | Code | Description |
---|---|---|
ATC | A10BD11 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD19 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD27 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BH05 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Dipeptidyl peptidase 4 (DPP-4) inhibitors |
MeSH PA | D054873 | Dipeptidyl-Peptidase IV Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006728 | Hormones |
MeSH PA | D007004 | Hypoglycemic Agents |
MeSH PA | D054795 | Incretins |
MeSH PA | D011480 | Protease Inhibitors |
FDA MoA | N0000175912 | Dipeptidyl Peptidase 4 Inhibitors |
FDA EPC | N0000175913 | Dipeptidyl Peptidase 4 Inhibitor |
CHEBI has role | CHEBI:35526 | hypoglycemic drug |
CHEBI has role | CHEBI:68612 | DPP-4 inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
Pancreatitis | contraindication | 75694006 | DOID:4989 |
Hypoglycemic disorder | contraindication | 237630007 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.16 | Basic |
pKa2 | 6.13 | Basic |
pKa3 | 3.79 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE) |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE) |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA) |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN) |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA) |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN) |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 10034877 | Aug. 5, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 9486526 | Aug. 5, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8853156 | March 5, 2031 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Dipeptidyl peptidase 4 | Enzyme | INHIBITOR | IC50 | 10 | CHEMBL | CHEMBL | |||
Dipeptidyl peptidase 9 | Enzyme | IC50 | 4 | CHEMBL | |||||
Muscarinic acetylcholine receptor M1 | GPCR | IC50 | 6.53 | CHEMBL | |||||
Prolyl endopeptidase FAP | Enzyme | IC50 | 7.05 | CHEMBL | |||||
Prolyl endopeptidase FAP | Enzyme | IC50 | 6.43 | CHEMBL | |||||
Dipeptidyl peptidase IV | Unclassified | IC50 | 5 | CHEMBL |
ID | Source |
---|---|
4030725 | VUID |
N0000182735 | NUI |
D09566 | KEGG_DRUG |
4030725 | VANDF |
C2746078 | UMLSCUI |
CHEBI:68610 | CHEBI |
356 | PDB_CHEM_ID |
CHEMBL237500 | ChEMBL_ID |
D000069476 | MESH_DESCRIPTOR_UI |
DB08882 | DRUGBANK_ID |
6318 | IUPHAR_LIGAND_ID |
9039 | INN_ID |
3X29ZEJ4R2 | UNII |
10096344 | PUBCHEM_CID |
1100699 | RXNORM |
181237 | MMSL |
27861 | MMSL |
d07767 | MMSL |
013732 | NDDF |
702798009 | SNOMEDCT_US |
703667006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0140 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 29 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0146 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 32 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0147 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 32 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0148 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 32 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0164 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0182 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Jentadueto XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0270 | TABLET, FILM COATED, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0275 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0380 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0385 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0390 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0395 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4383 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 29 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-6461 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 28 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0410 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 29 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-6524 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 31 sections |